Actively Recruiting
Phase I Study of Subcutaneous Durvalumab with Recombinant Human Hyaluronidase to Assess Drug Levels and Safety in Adults with Solid Tumors
Led by AstraZeneca · Updated on 2026-09-24
40
Participants Needed
19
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the use of subcutaneous under the skin durvalumab combined with recombinant human hyaluronidase rHu in adults with various solid tumors, including non-small cell lung cancer, hepatocellular carcinoma, and limited-stage small cell lung cancer. This Phase I, multicenter trial aims to find a subcutaneous dose that provides similar drug levels in the body as the intravenous form and to evaluate its pharmacokinetics and safety. The trial has two parts Part 1 involves dose escalation with two planned subcutaneous durvalumab dose levels DL1 and DL2 combined with rHu, followed by intravenous durvalumab at set intervals. Part 1 includes participants with different solid tumors. Part 2 begins after identifying the best dose from Part 1 and focuses on participants with unresectable hepatocellular carcinoma receiving the selected subcutaneous dose plus intravenous durvalumab. Some participants with hepatocellular carcinoma may also receive tremelimumab intravenously. Participants will undergo treatment and monitoring for about 17 months, during which researchers will assess drug levels over time and safety outcomes. Regular evaluations include measuring drug concentrations in blood, monitoring for adverse events and dose-limiting toxicities, and assessing disease status. This extensive follow-up helps understand how the drug behaves in the body and its safety profile over time.
CONDITIONS
Brief Title
A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here